Robot Babies Not Effective Birth Control, Study Finds

Related Link: 

A weekend spent mothering a robot baby to mirror the ‘real experience’ of parenting is meant to discourage teenage girls from getting pregnant. But so-called Baby Think it Over dolls don't cut teen pregnancy rates and in fact increase the risk, Australian research has found.

Fed Officials Voice Support for Activists' Issues

Related Link: 

Federal Reserve officials sought to reassure a group of labor activists that the central bank isn’t going to cool down the economy just as a stronger labor market is reaching a broader swath of Americans.

Theranos to Appeal Regulatory Sanctions

Related Link: 

Silicon Valley startup Theranos said it plans to appeal a decision made last month by regulators to revoke its license to operate a lab in California, among other penalties, because of unsafe practices.

Mylan's EpiPen Price Increases Highlight Its Grip on the Market

Related Link: 

The ability of Mylan to raise EpiPen’s list price by nearly 550% over the past eight years underscores the pricing power drug companies enjoy for iconic brands facing little competition.

From Bench to Benchmark: Jose Canseco Is Twitter's Favorite Financial Analyst

Related Link: 

Swapping OPS for NIRP, the ex-slugger tosses out predictions on Japanese monetary policy, gold and Brexit, hitting more than .300.

Janet Yellen Might Ruin Your Summer Vacation

Related Link: 

As investors debate whether markets are calm, the hope is Janet Yellen’s Jackson Hole speech provides more clarity than confusion.

What to Learn From the ECB's Great European Corporate Bond Squeeze

Related Link: 

The European corporate bond market is heading into ever more extraordinary territory.

Volkswagen Reaches Pact With Dealers Hurt by Emissions Scandal

Related Link: 

Volkswagen has reached an accord with about 650 U.S. franchise dealers affected by its diesel-emissions crisis but is struggling to convince regulators to accept a fix for some half a million polluting vehicles still on U.S. roads, even if they can’t be made fully compliant with emissions regulations.

Workday's Price for Getting the Job Done

Related Link: 

The cloud company’s valuation curbs enthusiasm, but performance stays strong.

The EpiPen Controversy Isn't About Mylan

Related Link: 

Political outrage over EpiPen price increases won’t help lower health-care costs for Americans.

Syndicate content